 Home > Active Ingredient News > Blood System > Blood Cancer J: Obituzumab + Atezolizumab + Lenalidomide can effectively treat relapsed/refractory follicular lymphoma!

Blood Cancer J: Obituzumab + Atezolizumab + Lenalidomide can effectively treat relapsed/refractory follicular lymphoma!

 Last Update: 2021-09-03
 Source: Internet
 Author: User

Tags

all type tomatoes

tergitol 15 9

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Follicular lymphoma (FL) is the most common type of indolent non-Hodgkin lymphoma (NHL)
.

Although the vast majority of treated FL patients can usually get remission from initial immunotherapy , most patients will eventually relapse and become less sensitive to subsequent treatment

Lymphoma immunity

Lenalidomide is an oral active immunomodulator with direct anti-tumor activity and indirect effects mediated by T cell and natural killer (NK) cell functions
.

Lenalidomide is an oral active immunomodulator with direct anti-tumor activity and indirect effects mediated by T cell and natural killer (NK) cell functions

Blood Cancer Journal Blood Cancer Journal

The initial phase of the trial used a 3+3 dose escalation design to clarify the recommended phase 2 dose of lenalidomide when G-atezo-len was used for induction and maintenance therapy in the subsequent expansion phase
.

Progression-free survival

In the final analysis, 38 patients (lenalidomide: 15 mg 4 patients, 20 mg 34 patients) completed the trial
.

The complete remission rate at the end of induction therapy was 71.

Duration of remission in 32 patients

All patients receiving study treatment had at least one adverse event (AE; Grade 3-5 AE: 32 cases [84%]; severe AE: 18 cases [47%]; 11 patients [29%] caused the study due to AE Interruption of treatment medication)
.

In addition, two fatal AEs occurred (one case of Merkel cell carcinoma and one case of sarcomatoid carcinoma; both cases were not related to the study medication)

All in all, the G-atezo-len regimen is an effective and well-tolerated treatment regimen for patients with relapsed/refractory follicular lymphoma
.

The adverse reactions of the combined regimen are the same as those of the three drugs when used alone, and no new safety issues have emerged

The G-atezo-len regimen is an effective and well-tolerated treatment regimen for patients with relapsed/refractory follicular lymphoma .

Original source:

Morschhauser Franck,Ghosh Nilanjan,Lossos Izidore S et al.

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed / refractory follicular lymphoma: final analysis of a Phase Ib / II trial in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.